Dr. Gil Price is a clinical physician trained in Internal medicine. He has a long-standing interest in novel drug development, drug utilization, pharmaceutical and biotechnology government regulation. He is an accomplished senior level manager with over 30 years of diverse therapeutic experience. His responsibilities have included clinical program development, global pharmacovigilance, and regulatory oversite.
Dr. Price currently serves as the Chief Medical Officer for ProPharma Group’s Pharmacovigilance team. Before joining ProPharma Group, Dr. Price served as CEO of Drug Safety Solutions, recently acquired by ProPharma Group. Dr. Price has also served as the Director of Clinical Development for oncology at MedImmune, Inc., the biologics subsidiary of AstraZeneca. Dr Price began his pharmaceutical career at Glaxo Inc. in Research Triangle Park, NC. While there, he worked nearly nine years in roles of increasing responsibility on both the commercial and research sides of the company.
Dr. Price is a former member of the American Medical Association, The Academy of Pharmaceutical Physicians and the American Society of Microbiology.